During the 24th European Hematology Association (EHA) Congress, researchers from the European branch of the Severe Chronic Neutropenia International Registry reported on experience with reference granulocyte colony-stimulating factor products and a biosimilar.
Patients who have severe chronic neutropenia, a rare groups of blood disorders that involve long periods of low levels of neutrophils, have benefitted from treatment with granulocyte colony-stimulating factor (G-CSF) therapies since their introduction in 1987.
During the 24th European Hematology Association (EHA) Congress, researchers from the European branch of the Severe Chronic Neutropenia International Registry reported on experience with reference G-CSF products—including filgrastim (Neupogen), pegfilgrastim (Neulasta), and lenograstim (Granocyte)—and a biosimilar filgrastim (Zarzio, also sold in Europe as Filgrastim Hexal).1
According to the investigators, 789 patients with severe chronic neutropenia—including congenital, cyclic, idiopathic, autoimmune, and other neutropenia—were enrolled in the European registry between 2011 and 2018, and 578 of them received G-CSF therapy.
Among these patients, 21 had received the biosimilar, and 16 of this group had switched from another G-CCSF product. Median treatment duration was 1.5 years (range, 0.1-4.4) and the median dose was 2.27 μg per kg per day (range, 0.25-40.0). Absolute neutrophil counts (ANC) during treatment showed that all patients responded well to the biosimilar, say the investigators, and ANCs were stable in patients who switched to the biosimilar from a branded drug.
Of the patients who received any G-CSF, 50 developed leukemia secondary to neutropenia. Only 1 of these patients had received the biosimilar. No cases of osteoporosis, severe splenomegaly, splenic rupture, severe side effects, or immunogenicity have been reported in patients who received the biosimilar.
In addition to the data presented on the biosimilar in the context of chronic neutropenia, the EHA congress also featured the presentation of data on the past decade of experience with the biosimilar.2
The authors of a narrative review of the evidence on Zarzio noted that post-approval studies have provided further evidence of the efficacy and safety of the biosimilar, particularly in the case of MONITOR-GCSF, which demonstrated, in sub-analyses, the efficacy and safety profile of the biosimilar in the prophylaxis of neutropenia in patients with multiple different tumor types.
In addition, data from studies of autologous stem cell mobilization show that the biosimilar is as safe and effective as the reference filgrastim, the authors note, and evidence is also accruing in the area of allogenic stem cell mobilization.
According to the review’s authors, the past 10 years of experience with the biosimilar, including 21 million patient days of exposure, show that the extrapolation of indications for biosimilars is based on strong scientific evidence and principles.
References
1. Zeidler C, Mellor-Heineke S, Nakov R, Natek M, Mathieson N, Gattu S. Patient with severe chronic neutropenia subtypes treated with biosimilar filgrastim: a study by the European branch of the severe chronic neutropenia international registry. Presented at: the 24th European Hematology Association Congress; June 13-16, 2019; Amsterdam, the Netherlands. Abstract PF353.
2. Gascón P, Mathieson N, Natek M, Krendyukov A, Aapro M. Ten years of clinical experience with biosimilar filgrastim in oncology and haematology. Presented at: the 24th European Hematology Association Congress; June 13-16, 2019; Amsterdam, the Netherlands. Abstract PF723.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.